Ultragenyx Pharmaceutical Inc (RARE)

Add to Watchlists
Create an Alert
63.11 +1.01  +1.63% NASDAQ Jul 22, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
08/02/2019 17:00 EDT Misc Ultragenyx Pharmaceutical Inc Second Quarter Earnings Conference Call in 2019
08/02/2019 Earnings Ultragenyx Pharmaceutical Inc Second Quarter Earnings in 2019 Release
06/11/2019 14:00 PDT Misc Ultragenyx Pharmaceutical Inc Annual General Meeting in 2018
05/06/2019 17:00 EDT Misc Ultragenyx Pharmaceutical Inc First Quarter Earnings Conference Call in 2019
05/06/2019 Earnings Ultragenyx Pharmaceutical Inc First Quarter Earnings in 2019 Release
02/20/2019 Misc Ultragenyx Pharmaceutical Inc Annual Report in 2018
02/19/2019 17:00 EST Misc Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings Conference Call in 2018
02/19/2019 Earnings Ultragenyx Pharmaceutical Inc Fourth Quarter Earnings in 2018 Release
11/05/2018 17:00 EST Misc Ultragenyx Pharmaceutical Inc Third Quarter Earnings Conference Call in 2018
11/05/2018 Earnings Ultragenyx Pharmaceutical Inc Third Quarter Earnings in 2018 Release
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.ultragenyx.com
  • Investor Relations URL: http://ir.ultragenyx.com/
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Growth
  • Next Earnings Release: Aug. 02, 2019
  • Last Earnings Release: May. 06, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Top Fund Holders

Symbol Name Weighting
GNOM Global X Genomics & Biotechnology ETF 3.59%
FBT First Trust NYSE Arca Biotech ETF 3.35%
BBP Virtus LifeSci Biotech Products ETF 2.67%
IMPAX ERShares US Small Cap Fund™ Inst 1.53%
XBI SPDR® S&P Biotech ETF 1.48%
HSZCX Highland Small-Cap Equity C 1.45%
KAUBX Federated Kaufmann B 1.34%
FKBSX Federated Kaufmann Small Cap B 1.20%
WSCAX Wanger International 1.15%

Comparables

Edit

Excel Add-In Codes

  • Name: =YCI("RARE","name")
  • Description: =YCI("RARE","description")
  • Sector: =YCI("RARE","sector")
  • Industry: =YCI("RARE","industry")
  • Est. Current Fiscal Year End: =YCI("RARE","fye")

To find the codes for any of our financial metrics, see our Complete Reference of Metric Codes.

Access our powerful Excel Add-in with a YCharts Professional Membership. Learn More.

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.